

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



四环医药  
*SihuanPharm*

**Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

**VOLUNTARY ANNOUNCEMENT**  
**TWO NON-PVC SOLID-LIQUID DOUBLE CHAMBER**  
**BAG PRODUCT INCLUDED IN THE NATIONAL DRUG**  
**REIMBURSEMENT LIST 2022**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, according to the “Notice on the Publication of the National Drug Reimbursement List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2022 Version)” (the “**NDRL 2022**”) officially issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security of the People’s Republic of China (the “**PRC**”), the “non-PVC solid liquid double chamber bag for ceftazidime/sodium chloride injection” and “non-PVC solid liquid double chamber bag for cefuroxime sodium/sodium chloride injection” (the “**non-PVC Solid-Liquid Double Chamber Bag Product**”) jointly developed by the Group and its associate company Beijing Ruiye Pharmaceutical Co., Ltd., are included in the NDRL 2022.

Non-PVC solid-liquid double chamber infusion soft bag has high technology barriers and long development cycle. It is an internationally advanced infusion product at present. The formulation utilises specific processes and uses non-PVC multi-layer co-extrusion film as packaging materials and encloses the drug and solvent injection into the two chambers of the same packaging, which are separated by empty solder. Before infusion, the user only needs to slightly squeeze the bottom of the chambers making them connected, allowing the drug powder and the solvent injection to be mixed with each other. This formulation avoids secondary contamination in the dispensing process caused by microorganisms and particles. It also avoids potential damage to medical staff caused by highly allergenic drugs that occur during the infusion preparation. In addition, as it takes less than 20 seconds from preparation to use and has the advantage of efficient and quick use, it can be

widely used in accident and emergency departments of hospitals and ICUs, saving more lives in emergencies. It has been recognized as the safest and most convenient infusion product for clinical application and is considered as one of the new formulations with great development potential in the pharmaceutical industry.

Compared with overseas markets, the development of the non-PVC Solid-Liquid Double Chamber Bag Product is still untapped in PRC, and the use of it only accounts for 20% of the total infusion market. Comparing to the market share of 40% to 60% in Japan and approximately 90% in the United States, it can be foreseen that it has broad market prospect and huge market potential in PRC. According to IQVIA data, the domestic sales of cephalosporin for injection was approximately RMB40 billion in 2021.

The anti-infection field has always been a key area of focus for the Group. The inclusion of the two non-PVC Solid-Liquid Double Chamber Bag Products in the NDRL 2022, also as the first and exclusive domestic formulation, is expected to create a certain degree of substitution for the existing products, and will have positive impact on the future expansion of the sales and market share, as well as the Company's operating results.

### **About Sihuan Pharmaceutical**

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and biopharmaceutical company led and driven by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic objective of "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 26 January 2023

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.*